• It may be appropriate to terminate a randomised controlled trial (RCT) prematurely for reasons of safety, if interim results suggest that finding a significant difference will be implausible (futility), when new external information has become available, or because patient recruitment is too slow. The practice of stopping trials early for apparent benefit, however, is more controversial.
• The aims of the current study were to generate an overview of the main arguments that are made for and against truncation of trials for apparent benefit and to assess whether Health Technology Assessment (HTA) agencies accept the increased uncertainty around overall survival (OS) estimates in oncology trials arising from early termination.
• A non-systematic medical literature search was conducted to gain different perspectives on the matter
• In addition, Quintiles' HTA Accelerator database 1 was screened for cancer technology appraisals published between January 2011 and September 2014
• In a first phase, NICE guidance documents in the field of oncology were reviewed to evaluate the potential impact of OS and progression-free survival (PFS) results on the agency's recommendations, to identify RCTs that were stopped early for apparent benefit, and to select interesting case examples
• In a second phase, related HTAs from other countries were reviewed to investigate local agencies' perspectives on data maturity and early trial termination
• The main arguments for and against early termination of trials for apparent benefit, as identified from the literature, are presented in table 2.
• The assertion that trials that are unblinded early for apparent benefit systematically overestimate treatment effects, supported by a study by Bassler et al 2 , was raised on several occasions by HTA agencies including NICE and HAS.
Case example: As part of the NICE evaluation of rituximab for the first-line maintenance treatment of patients with follicular non-Hodgkin's lymphoma, the Evidence Review Group adjusted the PFS hazard ratio (increased by 30.7%) from the PRIMA trial to account for "early reporting bias" in its sensitivity analyses 3 .
• As surrogate outcomes are often considered the primary endpoint(s) in oncology trials, these RCTs may not be powered and/or patients may not be followed-up long enough to allow detection of OS gains. While this approach may have been agreed upon with regulatory agencies as a requirement to obtain marketing authorisation, healthcare payers usually tend to have a greater focus on hard endpoints. In a recent EUnetHTA guideline, it is explained that decisions on the acceptability of intermediary outcomes are made on a case by case basis and can vary by country, but that PFS alone -without data on OS or at least on quality of life or other patient-relevant endpoints -is generally considered insufficient to carry out relative effectiveness assessments 4 . Our analysis of oncology TAs published by NICE since 2011 seems to confirm this statement ( Table 1 ).
• HTA agencies including NICE, SMC, HAS, PBAC, and IQWiG regularly criticise manufacturers for submitting "immature" survival data, regardless whether the related RCT was stopped prematurely. They may even issue a negative opinion on the grounds that there is too much uncertainty around the OS estimates to justify the manufacturer's proposed price level. Although there is no clear-cut definition of what constitutes mature OS data, comments issued by these HTA agencies suggest it is related to, either, reaching median overall survival or the death of 50% of patients in the study arms.
Case example: The CLEOPATRA trial, investigating pertuzumab vs. placebo as add-on to trastuzumab/docetaxel for HER 2 -positive locally advanced or metastatic breast cancer was unblinded early due to benefits observed in the 2nd interim analysis after 28% and 38% of patients had died, respectively. In draft guidance, NICE rejected pertuzumab because the data was considered too immature (could not predict how long the drug might extend people's lives) to support a price level that was much higher than existing treatments. In the meantime, final OS analysis has shown that pertuzumab can extend patients' lives by 15.7 months (figure 1) 5 .
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• While marketing authorisation may be granted on the basis of surrogate endpoints, robust OS data is essential to inform the cost-effectiveness analysis on which some HTA agencies and payers base their decisions
• In order to meet the information needs of HTA bodies, whenever possible, it is recommended to adopt conservative stopping rules ensuring that RCTs will be unblinded for apparent benefit only when a sufficient number of events have occurred, stringent statistical significance levels have been reached, and OS data are sufficiently mature 
Conclusions
Arguments pro Arguments contra
There is an ethical need to protect trial participants from an inferior treatment
Future patients that will undergo the intervention on the basis of potentially biased information far outnumber the trial population
Interim analyses may protect subjects from harm & various statistical stopping rules are available to deal with multiplicity (increased probability that multiple analyses may lead to significant results by chance alone)
All stopping rules are prone to stop the RCT in a "random high" and trials that are unblinded early for apparent benefit systematically overestimate treatment effects Non-significant Non-significant 1 -1
